Address:
Tel:
Web: http://www.lilly.com/Pages/home.aspx
We were founded by Eli Lilly in 1876, and are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has developed productive alliances and partnerships that advance our capacity to develop innovative medicines at lower costs. Lilly is consistently ranked as one of the best companies in the world to work for, and generations of Lilly employees have sustained a culture that values excellence, integrity, and respect for people.
Cancer
Alimta® (pemetrexed)
Gemzar® (gemcitabine hydrochloride)
Cardiology
Effient (prasugrel)
ReoPro® (abciximab) *
Cardiology/Pulmonary
Adcirca (tadalafil)
Diabetes
Byetta® (exenatide) injection** **
Glucagon™ (glucagon for injection [rDNA origin])
Humalog® (insulin lispro injection [rDNA origin])
Humalog® Mix75/25™ (75% Insulin lispro protamine suspension, 25% insulin lispro injection [rDNA origin])
Humalog® Mix50/50™ (50% Insulin lispro protamine suspension, 50% insulin lispro injection [rDNA origin])
Diabetic Peripheral Neuropathic Pain (DPNP)
Cymbalta® (duloxetine hydrochloride)
Erectile Dysfunction
Cialis® (tadalafil)
Fibromyalgia
Cymbalta® (duloxetine hydrochloride)
Growth Disorders
Humatrope® (somatropin rDNA origin for injection, Lilly)
Neuroscience
Cymbalta® (duloxetine hydrochloride)
Prozac® (fluoxetine hydrochloride)
Strattera®(atomoxetine hydrochloride)
Symbyax® (olanzapine and fluoxetine hydrochloride)
Zyprexa® (olanzapine)
Osteoporosis
Evista® (raloxifene hydrochloride)
Forteo® (teriparatide of recombinant DNA origin)
Sepsis
Xigris® (drotrecogin alfa [activated])
You joined Eli Lilly Poland in November 2008 as a Marketing Director and you have been leading the affiliate since January 2010. Moreover you are co-chairing the LAWG – Local…
Maciej Wieczorek, president of Celon Pharma, discusses the award-winning success of the 2016 IPO on the Warsaw stock exchange and the opportunities this has opened up, as well as investment…
Iwona Skrzekowska-Baran, owner and CEO of Pharm&Med, a young, exciting Polish consultancy that is helping clients to transform evidence, policy insights, and market intelligence into effective market access strategies. She…
Leonardo Maffioli, senior marketing and commercial manager of the fertility and endocrinology division of IBSA, discusses the story of IBSA Poland and the potential of the Polish market for the…
Jacek Glinka, president of Mylan Europe, and Tomasz Buczek, country manager of Mylan Poland, discuss the intricate dynamics of the European and Polish pharmaceutical ecosystem and the steps required to…
Witold Włodarczyk, director general of Polmed (Polish chamber for medical devices), discusses the Polish medical device landscape and the policy surrounding the sector, especially the proposed 2016 reimbursement act. Furthermore,…
Krzysztof Łokaj, general manager of Chiesi Poland, discusses the positioning of the company as they become the absolute leaders in the respiratory field, driven by Fostex® and soon Trimbow®. Furthermore,…
Dariusz Głogowski, country manager of Alvogen Poland, discusses his successful strategy to introduce biosimilars onto the Polish market and the nation’s moves to reward this new wave of generics. Furthermore,…
Agnieszka Grzybowska-Zalewska, general manager of Sanofi Genzyme Poland, reflects on the company’s stable growth over the last few years and the market access challenges they have encountered along the way.…
Dr. Wolfgang Wagner, regional director of Wörwag EU and CEE, highlights the ongoing process of the company to integrate itself within each respective healthcare community so patients can receive better…
Paweł Przewięźlikowski, CEO of Selvita, the largest biotech company between Germany and India, discusses the first-in-class and pioneer Polish molecule, SEL24, and the future game changing molecule, SEL120 – the…
Mieczysław Wośko, president and founder of Polfarmex, a leading Polish company, discusses the key factors behind the enterprise’s successful growth and the movement towards R&D to create their own treatments.…
Michał Mieszkowski, general manager of Angelini Poland, discusses the strategic significance of Poland for the company, as the third largest affiliate within the global company, the company’s impressive product portfolio…
See our Cookie Privacy Policy Here
